Xbrane has released the company’s 2025 Annual and Sustainability Report. The report summarizes business, financial performance and work on sustainability.

Annual

English

News

Regulatory

Report

VPML

” 2025 was a transformative year for Xbrane as we implemented a new strategic direction. Our strategy now focuses on two biosimilar candidates, Ximluci® and Xdivane™, enabling us to reduce our cost base while maximizing shareholder value. The divestment of our Cimzia™ biosimilar project, together with parts of our organization, to Alvotech strengthened our balance sheet and significantly lowered our operating costs”, says Anders Tullgren, Chairman of the Board.

Xbrane Biopharma AB’s annual report for 2025 is now available at the company’s website, www.xbrane.com.
The annual report includes the corporate governance report and the sustainability report for 2025. The Report is distributed to the shareholders and others that made such requests. It can also be ordered from Xbrane Biopharma at the following address:

Xbrane Biopharma AB
Scheeles väg 5
171 65 Solna
Sweden
Or via e-mail: ir@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com